Dr Saadiya Siddiqui Saadiya, Shanze Shafiq, Amna Arif, Shahbaz Aman
{"title":"甲氨蝶呤与阿维甲素治疗慢性斑块型银屑病的疗效比较","authors":"Dr Saadiya Siddiqui Saadiya, Shanze Shafiq, Amna Arif, Shahbaz Aman","doi":"10.51273/esc23.251914","DOIUrl":null,"url":null,"abstract":"Objective: To compare the efficacy of methotrexate versus acitretin in the treatment of chronic plaque psoriasis Method: Randomized controlled Trial conducted in Dermatology Department, Services Hospital Lahore, on 60 patients after informed consent, divided into two groups. Group A given methotrexate 0.30.5mg/kg orally and group B given acitretin 0.4mg/kg orally. Efficacy was ascertained by reduction in PASI score, calculated at baseline and at the 12 weeks. Results:Patients of Group A achieved a reduction in PASI score from baseline 13.13±2.047 to 6.20±2.024 (efficacy 76.7%) while in Group B, PASI score dropped from 13.53±2.047 to 7.00±1.857 (efficacy 56.7%). Adverse effects for both groups were minimal and as expected. Conclusion: Both methotrexate and acitretin are highly effective drugs in treating chronic plaque psoriasis. However, methotrexate shows greater efficacy and faster reduction in PASI as compared to acitretin.","PeriodicalId":11923,"journal":{"name":"Esculapio","volume":"4 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comparison of efficacy of Methoterexate versus Acitretin in the treatment of chronic plaque psoriasis\",\"authors\":\"Dr Saadiya Siddiqui Saadiya, Shanze Shafiq, Amna Arif, Shahbaz Aman\",\"doi\":\"10.51273/esc23.251914\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: To compare the efficacy of methotrexate versus acitretin in the treatment of chronic plaque psoriasis Method: Randomized controlled Trial conducted in Dermatology Department, Services Hospital Lahore, on 60 patients after informed consent, divided into two groups. Group A given methotrexate 0.30.5mg/kg orally and group B given acitretin 0.4mg/kg orally. Efficacy was ascertained by reduction in PASI score, calculated at baseline and at the 12 weeks. Results:Patients of Group A achieved a reduction in PASI score from baseline 13.13±2.047 to 6.20±2.024 (efficacy 76.7%) while in Group B, PASI score dropped from 13.53±2.047 to 7.00±1.857 (efficacy 56.7%). Adverse effects for both groups were minimal and as expected. Conclusion: Both methotrexate and acitretin are highly effective drugs in treating chronic plaque psoriasis. However, methotrexate shows greater efficacy and faster reduction in PASI as compared to acitretin.\",\"PeriodicalId\":11923,\"journal\":{\"name\":\"Esculapio\",\"volume\":\"4 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-05-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Esculapio\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.51273/esc23.251914\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Esculapio","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.51273/esc23.251914","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Comparison of efficacy of Methoterexate versus Acitretin in the treatment of chronic plaque psoriasis
Objective: To compare the efficacy of methotrexate versus acitretin in the treatment of chronic plaque psoriasis Method: Randomized controlled Trial conducted in Dermatology Department, Services Hospital Lahore, on 60 patients after informed consent, divided into two groups. Group A given methotrexate 0.30.5mg/kg orally and group B given acitretin 0.4mg/kg orally. Efficacy was ascertained by reduction in PASI score, calculated at baseline and at the 12 weeks. Results:Patients of Group A achieved a reduction in PASI score from baseline 13.13±2.047 to 6.20±2.024 (efficacy 76.7%) while in Group B, PASI score dropped from 13.53±2.047 to 7.00±1.857 (efficacy 56.7%). Adverse effects for both groups were minimal and as expected. Conclusion: Both methotrexate and acitretin are highly effective drugs in treating chronic plaque psoriasis. However, methotrexate shows greater efficacy and faster reduction in PASI as compared to acitretin.